Phase 3 Registrational Trial Seeks to Improve Survival Outcomes in Underserved HPV-negative R/M Head and Neck Cancer Patient PopulationTrial Launch Follows FDA Fast Track Designation of.
The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.The benefit appeared confined to individuals with HPV-negative disease, and a phase 3 trial to further evaluate the regimen in that population is planned.
Unusual drug combo shows promise for advanced head, neck cancer without HPV miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
New cancer treatments may be on the horizon—thanks to mRNA vaccines nationalgeographic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationalgeographic.com Daily Mail and Mail on Sunday newspapers.